NCT07169500

Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Evaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients

Detailed description

This study is a single-center, open-label, prospective investigator-initiated clinical study. Patients are assigned to treatment groups in a non-randomized manner based on their condition and disease status, and are divided into transplant and non-transplant groups according to whether ASCT is combined. The study analyzes and compares the safety and efficacy of BCMA-CART ± ASCT treatment in young MM patients.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	CAR-T	Chimeric antigen receptor T cells (car-t) are genetically engineered MHC independent tumor specific killer cells.

Timeline

• Start date: 2025-03-03
• Primary completion: 2028-03-02
• Completion: 2030-03-02
• First posted: 2025-09-11
• Last updated: 2026-03-02

Locations

1 site across 1 country: China